Skip directly to content

SiteMap

Important Safety Information

XALATAN® (latanoprost ophthalmic solution) is not recommended in patients with a known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product.

XALATAN may slowly cause darkening of the eye color, darkening of the eyelid and eyelashes, and increased growth and thickness of eyelashes. Color changes may increase as long as XALATAN is administered, and eye color changes are likely to be permanent.

There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products.

Contact lenses should be removed prior to the administration of XALATAN. Contact lenses can be reinserted 15 minutes following administration of XALATAN.

The most common side effects for XALATAN may include blurred vision, burning and stinging, eye redness, eye itching, the feeling of something in the eye, increased darkening of eye color, irritation of the clear front surface of the eye, or cold or flu.

Indication

XALATAN is a prescription medication for the treatment of high eye pressure/intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension.

Patients should always ask their doctors for medical advice about adverse events.

You may report an adverse event related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where health care professionals and consumers can report serious problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit MedWatch or call 1-800-FDA-1088.

You are leaving XALATAN.com

You are leaving this website. Links to all outside websites are provided as a convenience to our visitors and do not imply an endorsement or recommendation by Pfizer. Pfizer accepts no responsibility or liability for the content or services of other websites.